SynthesisHuman molecular genetics2016
A genome-wide association meta-analysis on apolipoprotein A-IV concentrations.
Open access · bronzeAbstract readMeta-Analysis
In one paragraph
Synthesis in Human molecular genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Genetic architecture and cross-platform validation of apolipoprotein A-IV concentrations.Genome biology · 2026Pooled it
- A deep ensemble encoder network method for improved polygenic risk score prediction.BioData mining · 2026Article
- Gene clusters linked to insulin resistance identified in a genome-wide study of the Taiwan Biobank population.Nature communications · 2025Article
- Therapeutic potential of simvastatin in ALS: Enhanced axonal integrity and motor neuron survival through Apoa4 and Alb modulation.Biomolecules & biomedicine · 2025Article
- Closing the gaps in patient management of dyslipidemia: stepping into cardiovascular precision diagnostics with apolipoprotein profiling.Clinical proteomics · 2024Review
- Genetics of osteopontin in patients with chronic kidney disease: The German Chronic Kidney Disease study.PLoS genetics · 2022Article
- Kallikrein augments the anticoagulant function of the protein C system in thrombin generation.Journal of thrombosis and haemostasis : JTH · 2022Article
- Single-cell RNA sequencing reveals a novel inhibitory effect of ApoA4 on NAFL mediated by liver-specific subsets of myeloid cells.Frontiers in immunology · 2022Article
- Depression Augments Plasma APOA4 without Changes of Plasma Lipids and Glucose in Female Adolescents Carrying G Allele of APOA4 rs5104.Journal of molecular neuroscience : MN · 2021Article
- Gene networks and pathways for plasma lipid traits via multitissue multiomics systems analysis.Journal of lipid research · 2021Article
- Article
- Kidney as modulator and target of "good/bad" HDL.Pediatric nephrology (Berlin, Germany) · 2019Review
- Apolipoprotein A-IV: A Multifunctional Protein Involved in Protection against Atherosclerosis and Diabetes.Cells · 2019Review
- Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk.Journal of lipid research · 2018Article
- HDL in CKD-The Devil Is in the Detail.Journal of the American Society of Nephrology : JASN · 2018Review
- Heritability and Genome-Wide Association Study of Plasma Cholesterol in Chinese Adult Twins.Frontiers in endocrinology · 2018Article
- Genetic influences on the human oral microbiome.BMC genomics · 2017Article
- Evaluating the Causal Relation of ApoA-IV with Disease-Related Traits - A Bidirectional Two-sample Mendelian Randomization Study.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 15 institutions in 7 countries.
Claudia LaminaDivision of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.
Salome FriedelDivision of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.
Stefan CoassinDivision of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.
Rico RueediDepartment of Computational Biology, University of Lausanne, Lausanne, Switzerland.
Noha A YousriDepartment of Physiology and Biophysics, Weill Cornell Medical College - Qatar, Doha, Qatar.
Ilkka SeppäläDepartment of Clinical Chemistry, Fimlab Laboratories and University of Tampere School of Medicine, Tampere, Finland.
Christian GiegerInstitute of Genetic Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health.
Sebastian SchönherrDivision of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.
Lukas ForerDivision of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.
Gertraud ErhartDivision of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.
Barbara KolleritsDivision of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.
Pedro Marques-VidalDepartment of Medicine, Internal Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Janina RiedInstitute of Genetic Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health.
Gerard WaeberDepartment of Medicine, Internal Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Sven BergmannDepartment of Computational Biology, University of Lausanne, Lausanne, Switzerland.
Doreen DähnhardtDivision of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.
Andrea StöcklDivision of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.
Stefan KiechlDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Olli T RaitakariDepartment of Clinical Physiology, Turku University Hospital, Turku, Finland.
Mika KähönenDepartment of Clinical Physiology, Tampere University Hospital and University of Tampere, Tampere, Finland.
Johann WilleitDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Ludmilla KedenkoFirst Department of Internal Medicine, Paracelsus Private Medical University, Salzburg, Austria.
Bernhard PaulweberFirst Department of Internal Medicine, Paracelsus Private Medical University, Salzburg, Austria.
Annette PetersInstitute of Epidemiology II, Helmholtz Zentrum München-German Research Center for Environmental Health.
Thomas MeitingerInstitute of Human Genetics, Technische Universität München, München, Germany.
Konstantin StrauchInstitute of Genetic Epidemiology, Helmholtz Zentrum München-German Research Center for Environmental Health.
KORA Study Group
Terho LehtimäkiDepartment of Clinical Chemistry, Fimlab Laboratories and University of Tampere School of Medicine, Tampere, Finland.
Steven C HuntCardiovascular Genetics Division, University of Utah School of Medicine, Salt Lake City, UT, USA.
Peter VollenweiderDepartment of Medicine, Internal Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Florian KronenbergDivision of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.
Universität Innsbruck · ATInnsbruck Medical University · ATUniversity Hospital of Lausanne · CHCenter for Environmental Health · USFimlab (Finland) · FIParacelsus Medical University · ATAlexandria University · EGGerman Centre for Cardiovascular Research · DEHelmholtz Zentrum München · DEMunich Cluster for Systems Neurology · DESIB Swiss Institute of Bioinformatics · CHTampere University · FIUniversity of Lausanne · CHUniversity of Turku · FIWeill Cornell Medical College in Qatar · QA
Funding
GENCAC-Data Coordinating CenterU01HL067899 · NHLBI · WASHINGTON UNIVERSITY · PI PROVINCE, MICHAEL A · 2001 to 2004
$1.4MGENCAC - Utah Field CenterU01HL067894 · NHLBI · UNIVERSITY OF UTAH · PI HUNT, STEVEN C. · 2001 to 2004
$1.3MGENCAC - Arterial Calcium Reading CenterU01HL067897 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI CARR, JOHN JEFFREY · 2001 to 2004
$1.2MGENCAC - Minnesota Field CenterU01HL067901 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI PANKOW, JAMES S · 2001 to 2004
$1.1MGENCAC - Birmingham Field CenterU01HL067898 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEWIS, CORA E · 2001 to 2004
$1.0MGENCAC - MOLECULAR GENETICS LABORATORYU01HL067902 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HIXSON, JAMES E. · 2001 to 2004
$1.0MGENCAC - North Carolina Field CenterU01HL067895 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI WAGENKNECHT, LYNNE E · 2001 to 2004
$989kGENCAC - Framingham Field CenterU01HL067896 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ELLISON, CURTIS R. · 2001 to 2004
$971kGENCAC - CENTRAL BIOCHEMISTRY LABORATORYU01HL067900 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI ECKFELDT, JOHN H · 2001 to 2004
$884kGenetics of Coronary and Aortic Calcification (GENCAC)U01HL067893 · NHLBI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI HEISS, GERARDO · 2001 to 2004
$818kAustrian Science Fund FWF P 26660NHLBI NIH HHS U01 HL067893NHLBI NIH HHS U01 HL067894NHLBI NIH HHS U01 HL067895NHLBI NIH HHS U01 HL067896NHLBI NIH HHS U01 HL067897NHLBI NIH HHS U01 HL067898NHLBI NIH HHS U01 HL067899NHLBI NIH HHS U01 HL067900NHLBI NIH HHS U01 HL067901NHLBI NIH HHS U01 HL067902
Abstract
Apolipoprotein A-IV (apoA-IV) is a major component of HDL and chylomicron particles and is involved in reverse cholesterol transport. It is an early marker of impaired renal function. We aimed to identify genetic loci associated with apoA-IV concentrations and to investigate relationships with known susceptibility loci for kidney function and lipids. A genome-wide association meta-analysis on apoA-IV concentrations was conducted in five population-based cohorts (n = 13,813) followed by two additional replication studies (n = 2,267) including approximately 10 M SNPs. Three independent SNPs from two genomic regions were significantly associated with apoA-IV concentrations: rs1729407 near APOA4 (P = 6.77 × 10
Indexed as
Genome-Wide Association StudyAllelesApolipoproteins ACholesterol, HDLFemaleHumansKidneyLipidsMalePolymorphism, Single NucleotideTriglyceridesapolipoprotein A-IVApolipoproteins ACholesterol, HDLLipidsTriglycerides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.